Prudential Financial
VTGN icon

Prudential Financial’s VistaGen Therapeutics VTGN Stock Holding History

Prudential Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,100
Closed -$30.3K – 2599
2026
Q1 		$30.3K Buy
+53,100
New +$32.3K ﹤0.01% 2362
2023
Q2 		– Sell
-336
Closed -$1.25K – 2718
2023
Q1 		$1.25K Hold
336
– – ﹤0.01% 2598
2022
Q4 		$1.04K Hold
336
– – ﹤0.01% 2590
2022
Q3 		$2K Hold
336
– – ﹤0.01% 2645
2022
Q2 		$9K Hold
336
– – ﹤0.01% 2654
2022
Q1 		$12K Hold
336
– – ﹤0.01% 2592
2021
Q4 		$20K Sell
336
-43
-11% -$2.8K ﹤0.01% 2613
2021
Q3 		$31K Sell
379
-39
-9% -$3.39K ﹤0.01% 2567
2021
Q2 		$39K Buy
+418
New +$31K ﹤0.01% 2527

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Prudential Financial's VTGN Position: Q2 2026 in Review

Prudential Financial sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 53,100 shares — an estimated $30.3K sold.

Prudential Financial first reported a position in VTGN in Q2 2021 and held it in 9 quarters. The position peaked at $39K in Q2 2021. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Prudential Financial reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prudential Financial sold 53,100 VistaGen Therapeutics shares in Q2 2026, an estimated $30.3K.
  • Prudential Financial first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 9 quarters.
  • Prudential Financial's VistaGen Therapeutics position peaked at $39K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.